Hengrui Medicine gains approval for remimazolam clinical trials

Jiangsu Hengrui Medicine (SSE:600276) announced that it has received approval from the National Medical Products Administration of China to conduct clinical trials for its remimazolam injection. The trials will focus on the use of remimazolam for sedation in children and adolescents aged 3-17 undergoing general anesthesia for surgical procedures. Hengrui currently has remimazolam injection products approved for sedation and anesthesia during procedures, and for induction and maintenance of general anesthesia. Remimazolam, a short-acting GABAa receptor agonist, generated approximately USD 50.059 million in global sales in 2023. The company has invested CNY 172.53 million in related research and development. Hengrui Medicine cautioned that the drug still requires clinical trials and regulatory approval before it can be commercialized, and there are risks associated with its development.